Global mAb Biosimilars Market 2016-2020

2016-09-23
Price :
Published : Sep-2016
No. of Pages : 103

Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.

The analysts forecast spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of more than 57% during the period 2015-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.

The market is divided into the following segments based on geography:

  • Europe
  • Asia
  • ROW

The report, Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Biocon
  • Celltrion
  • Dr. Reddy’s Laboratories
  • Hospira

Other prominent vendors

  • 3SBio
  • Accord Healthcare
  • AET Biotech
  • Allergan
  • Alvartis Pharma
  • Amega Biotech
  • Amgen
  • Apotex
  • Aspen
  • AstraZeneca
  • Aurobindo Pharma
  • Baxter
  • Bharat Serums
  • Bio Sidus
  • Biogen
  • Bionovis
  • Bioton
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Boston Oncology
  • Cipla
  • Coherus Biosciences
  • Daiichi Sankyo
  • Emcure Pharmaceuticals
  • Gedeon Richter
  • GeneScience Pharmaceuticals
  • GSK
  • Hetero Drugs
  • iBio
  • Intas Pharmaceuticals
  • JCR Pharmaceuticals
  • LG Lifesciences
  • Lonza
  • Merck
  • Mitsubishi Tanabe Pharma
  • Momenta Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Novartis
  • Pfenex
  • Pfizer
  • Ranbaxy Laboratories
  • Roche Holding
  • Samsung Biologics
  • Sanofi
  • Synthon

Market driver

  • •Rise in number of patent expiries
  • For a full, detailed list, view our report

Market challenge

  • Physicians’ reluctance to prescribe biosimilars
  • For a full, detailed list, view our report

Market trend

  • Emergence of biosimilars
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2026

EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2026 Summary Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE (AHA, 2017). Our epidemiologists forecast an increase in the diagnosed inciden......
$3995

Chlamydia Tests – Medical Devices Pipeline Assessment, 2017

Chlamydia Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData's Medical Devices sector report, "Chlamydia Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Chlamydia Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Chlamydia Tests pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team o......
$2500

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2016. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the......
$3500

EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026

EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026 Summary GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland (CGF, 2003). The ICD-10 Clinical Modification (ICD-10-CM) code for GHD is E23.0. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth, in which case it is known as congenital, or it can be secondary due to brain trauma and is known as acquired. The signs and symptoms of the disease can vary. Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. GHD in children affects growth and development. In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes ......
$3995

Top Trends in Healthcare and OTC 2017: Exploring OTC medication, vitamins, minerals and supplements; functional food and drink; and sports nutrition categories

Global consumers are becoming more health-conscious as a reaction to rising obesity levels and lifestyle-related illnesses, such as diabetes, in the modern world. Consumers' busy lives are a major driver for the healthcare and OTC market as people opt for more convenient, multifunctional, and personalized products that better target their specific needs. Over-the-counter (OTC) drugs are those sold directly to a consumer without a prescription from a healthcare professional, as compared to prescription drugs, which may be sold only to consumers possessing a valid prescription. The pressures of modern life are taking their toll on consumers as their increasingly hectic lifestyles, due to work, active social lives and family responsibilities, means that stress is the most concerning hea......
$3450

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Germany

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany Summary Germany has a mature healthcare market based on its high healthcare expenditure and pharmaceutical production. The increasingly elderly population and its associated disease burden are expected to drive the growth of the pharmaceutical market, while government initiatives to reduce healthcare expenditure will limit growth. The value of the German pharmaceuticals market increased from EUR37.3 Billion (US$54.7 Billion) in 2008 to EUR43.3 Billion (US$57.6 Billion) in 2013 at a Compound Annual Growth Rate (CAGR) of 1.0%. In US dollar terms, the market declined from US$54.7 Billion in 2008 to US$51.2 Billion in 2012 at a negative CAGR of 1.7% due to frequent currency devaluation. The value of the pharmaceutica......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Data prese......
$1000

Underground Gas Storage Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites

Underground Gas Storage Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites Summary "Underground Gas Storage Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites", is a comprehensive report on underground gas storage industry in Europe. The report provides gas storage site details such as asset name, operator name, storage type, start year, working gas capacity along with withdrawal rate for all active and planned gas storage assets in the region. The report also provides key country comparisons based on contribution to working gas capacity. The report also provides capital expenditure outlook by key countries, year on year, ......
$5000

Underground Gas Storage Industry Outlook in North America to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites

Underground Gas Storage Industry Outlook in North America to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites Summary "Underground Gas Storage Industry Outlook in North America to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites", is a comprehensive report on underground gas storage industry in North America. The report provides gas storage site details such as asset name, operator name, storage type, start year, working gas capacity along with withdrawal rate for all active and planned gas storage assets in the region. The report also provides key country comparisons based on contribution to working gas capacity. The report also provides capital expenditure outlook by key coun......
$5000

Underground Gas Storage Industry Outlook In Former Soviet Union To 2021: Capacity And Capital Expenditure Forecasts With Details Of All Operating And Planned Storage Sites

Underground Gas Storage Industry Outlook In Former Soviet Union To 2021: Capacity And Capital Expenditure Forecasts With Details Of All Operating And Planned Storage Sites Summary "Underground Gas Storage Industry Outlook In Former Soviet Union To 2021: Capacity And Capital Expenditure Forecasts With Details Of All Operating And Planned Storage Sites", is a comprehensive report on underground gas storage industry in Former Soviet Union. The report provides gas storage site details such as asset name, operator name, storage type, start year, working gas capacity along with withdrawal rate for all active and planned gas storage assets in the region. The report also provides key country comparisons based on contribution to working gas capacity. The report also provides capital expenditure o......
$5000